19 research outputs found

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Copyright (c)JCPDS-International Centre for Diffraction Data 2002, Advances in X-ray Analysis, Volume 45. 539 ANALYSIS OF LEAD IN CANDLE PARTICULATE EMISSIONS BY XRF USING UNIQUANT ® 4

    No full text
    As part of an extensive program to study the small combustion sources of indoor fine particulate matter (PM), candles with lead-core wicks were burned in a 46-L glass flow-through chamber. The particulate emissions with aerodynamic diameters <10:m (PM 10) were captured on quartz filters and analyzed under vacuum in a Philips PW 2404 wavelength-dispersive X-Ray Fluorescence (WDXRF) Spectrometer. UniQuant ® 4 software was used to calculate the filter lead concentrations. Particulate filter loading masses ranged from 0.18 to 52.1 mg. The lead concentrations ranged from 0.2 to 80 % by weight, with carbon comprising the remainder of the matrix. The method was validated by analyzing 87 filters, first by XRF and then by EPA Method 12 atomic absorption spectroscopy (AAS). For 84 filters, the average particle mass recovery after XRF analysis was 99 ± 6%. For 84 filters analyzed for lead by both methods, the average recovery of lead by XRF compared to the AAS analysis was 108 ± 9%. Modeling of candle emissions using typical room ventilation scenarios showed that even low-emitting candles can produce a lead concentration above the EPA National Ambient Air Quality Standard (NAAQS) of 1.5:g/m 3 (quarterly average). Burning more than one heavily emitting candle in a poorly ventilated space can produce concentrations exceeding the Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (PEL) concentration of 50:g/m 3 (8-hour time-weighted average)
    corecore